Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800953 | 0.97 | LMNA (0.63) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL2994810 | 0.97 | LMNA (0.63) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28224901 | 0.97 | LMNA (0.63) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1270397 | 0.94 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL9542319 | 0.94 | LMNA (0.78) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL19392377 | 0.94 | LMNA (0.67) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL93800 | 0.94 | LMNA (0.67) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL28724453 | 0.91 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29843605 | 0.91 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL149808 | 0.91 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120058495-A | Process for the preparation of mixed alkyl ketones and alkyl alcohols | 武汉希音新材料科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-118993844-A | Process for the preparation of mixed alkyl ketones and alkyl alcohols | 武汉希音新材料科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | BIOSYNTHIS (FR) | 2025-06-19 | — | — | US | disclosed |
| CN-120058495-A | Process for the preparation of mixed alkyl ketones and alkyl alcohols | 武汉希音新材料科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| CN-118993844-A | Process for the preparation of mixed alkyl ketones and alkyl alcohols | 武汉希音新材料科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-5118511-A | Emulsifier, protective colloid, drug dispersed in very small particles of edible oil or fat | BASF AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| US-4935245-A | DISSOLVED IN SMALL DROPS OF EDIBLE OIL OR FAT | BASF AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | LMNA 3717/4885BLM 1093/4885PTPN1 4299/4885 |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | FASN, SCD5, NFKB2 | LMNA 149/4885BLM 4294/4885PTPN1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.